8.43
CorMedix Inc stock is traded at $8.43, with a volume of 792.58K.
It is down -0.47% in the last 24 hours and up +12.10% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$8.47
Open:
$8.45
24h Volume:
792.58K
Relative Volume:
0.62
Market Cap:
$657.07M
Revenue:
$400.05M
Net Income/Loss:
$181.01M
P/E Ratio:
4.0156
EPS:
2.0993
Net Cash Flow:
$194.58M
1W Performance:
+1.57%
1M Performance:
+12.10%
6M Performance:
+18.40%
1Y Performance:
-34.14%
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CRMD
CorMedix Inc
|
8.43 | 641.48M | 400.05M | 181.01M | 194.58M | 2.0993 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
CorMedix Inc. (CRMD) Latest Stock News & Headlines - finance.yahoo.com
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet - Yahoo Finance
Bank of New York Mellon Corp Takes Position in CorMedix Inc $CRMD - MarketBeat
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge - Stocktwits
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
The Technical Signals Behind (CRMD) That Institutions Follow - news.stocktradersdaily.com
Cormedix Stock Price Forecast. Should You Buy CRMD? - StockInvest.us
CorMedix Inc (NASDAQ: CRMD) Share Price, CRMD Stock News, CRMD Share Price & Updates - kalkine.ca
243,232 Shares in CorMedix Inc $CRMD Purchased by Empowered Funds LLC - MarketBeat
CRMD|CorMedix Inc|Price:8.430|Chg%:-0.040 - TradingKey
CorMedix (CRMD) COO holds 270K shares after cost-covering share withholding - Stock Titan
CorMedix will meet investors in Boston for a Wells Fargo chat - Stock Titan
BlackRock Inc. Acquires Shares of 6,324,111 CorMedix Inc $CRMD - MarketBeat
CorMedix (CRMD) Upgraded to Buy: Here's Why - Yahoo Finance
Equity award costs paid in stock at CorMedix (CRMD) - Stock Titan
CRMD's Growth Story Expands Beyond DefenCath Into New Trends - Eastern Progress
CorMedix (CRMD) Results at a Glance: EPS Exceeds Its Estimate in Latest Trading; Shares Move Lower 0.72% on the DayTech Earnings Analysis - vinanet.vn
CorMedix (CRMD) Q2 2026 Earnings Call Transcript - AOL.com
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade - Yahoo Finance
CorMedix (CRMD) Momentum: Moves 0.12% Up to $8.18 in the Current Update; Range View: Traders Can Monitor the $7.77-$8.59 Range in Latest TradingETF Creation Redemption - vinanet.vn
CorMedix (CRMD) Price Action: Ends Up by 6.19% at $8.14 on the Day; Chart Reference: the Near-Term Reference Band Stretches From $7.73 to $8.55 in the Latest SessionReversal Setup Alerts - Vinanet
Research Analysts Set Expectations for CorMedix Q3 Earnings - MarketBeat
CRMD Q2 2026 Earnings: EPS of $0.29 Beats Consensus by 19.4%EPS Guidance Update - Vinanet
CorMedix: Durable Commercial Base, But 2027 Is The Real Test (NASDAQ:CRMD) - Seeking Alpha
CorMedix (NASDAQ:CRMD) Shares Up 7.3% on Analyst Upgrade - MarketBeat
FY2026 EPS Estimates for CorMedix Raised by HC Wainwright - MarketBeat
(CRMD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
CorMedix Inc (CRMD) Stock News Today - TradingKey
CorMedix Stock Jumps on Strong DefenCath Sales - Sahm
Full Transcript: Cormedix Q2 2026 Earnings Call - Sahm
CorMedix (NASDAQ:CRMD) Shares Down 4.6%Here's Why - MarketBeat
Royal Bank Of Canada Issues Positive Forecast for CorMedix (NASDAQ:CRMD) Stock Price - MarketBeat
CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says - marketscreener.com
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains - The Globe and Mail
RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating - Moomoo
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
H.C. Wainwright reiterates CorMedix stock rating on strong quarter - Investing.com
H.C. Wainwright reiterates CorMedix stock rating on strong quarter By Investing.com - Investing.com India
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
CorMedix (CRMD) Q2 2026 Earnings Call: Revenue Hits $101.9M, EBITDA Guidance Raised - TradingKey
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CorMedix Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CorMedix Shares Surge 17% as Q2 Revenue Tops $100 Million, EBITDA Outlook Raised - finance.biggo.com
CorMedix Q2 2026 Earnings Call Transcript - MarketBeat
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
CorMedix (CRMD) Surges 14.65% to $8.14 as Biotech Momentum Builds Toward ResistanceALMA Signal - Vinanet
CorMedix Shares Rise After Q2 Results, Guidance - marketscreener.com
CorMedix (NASDAQ:CRMD) Releases Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
CorMedix Q2 revenue hits $101.9M; DEFSEC up 92% YoY - scanx.trade
CorMedix Q2 Earnings Call Highlights - MarketBeat
CorMedix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):